CYT insider filings

Cyteir Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-03-25. Screen CYT transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for CYT between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Cyteir Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2024-03-254Leonard Braden Michael — 10% ownerPurchase (P): 170,589 @ $2.95EDGAR
2024-03-194Leonard Braden Michael — 10% ownerPurchase (P): 113,777 @ $3.01EDGAR
2024-03-054Gaiero David G — Chief Financial OfficerOption exercise (M): 3,239 @ $1.68 · Option exercise (M): 4,746 @ $1.69 · Option exercise (M): 2,373 @ $1.69 · Option exercise (M): 3,239 (derivative) @ $0 · Option exercise (M): 4,746 (derivative) @ $0 · Option exercise (M): 2,373 (derivative) @ $0EDGAR
2024-03-054RENSCHLER MARKUS MD — President and CEO, DirectorOption exercise (M): 12,607 @ $1.69 · Option exercise (M): 2,537 @ $1.20 · Option exercise (M): 6,304 @ $1.69 · Option exercise (M): 12,607 (derivative) @ $0 · Option exercise (M): 2,537 (derivative) @ $0 · Option exercise (M): 6,304 (derivative) @ $0EDGAR
2024-02-164George Jean — DirectorOption exercise (M): 14,150 @ $1.69 · Option exercise (M): 14,150 (derivative) @ $0EDGAR
2024-02-144Sands Stephen H. — DirectorOption exercise (M): 12,129 @ $1.69 · Option exercise (M): 12,129 (derivative) @ $0EDGAR
2024-02-124THERO JOHN F — DirectorOption exercise (M): 12,828 @ $1.69 · Option exercise (M): 12,828 (derivative) @ $0EDGAR
2024-02-084Zakrzewski Joseph S — DirectorOption exercise (M): 14,150 @ $1.69 · Option exercise (M): 14,150 (derivative) @ $0EDGAR
2023-12-144Gaiero David G — Chief Financial OfficerOption exercise (M): 1,620 @ $1.68 · Option exercise (M): 2,373 @ $1.69 · Option exercise (M): 1,620 (derivative) @ $0 · Option exercise (M): 2,373 (derivative) @ $0EDGAR
2023-12-144RENSCHLER MARKUS MD — President and CEO, DirectorOption exercise (M): 6,304 @ $1.69 · Option exercise (M): 2,536 @ $1.20 · Option exercise (M): 6,304 (derivative) @ $0 · Option exercise (M): 2,536 (derivative) @ $0EDGAR
2023-11-224Gaiero David G — Chief Financial OfficerOption exercise (M): 52,584 @ $1.68 · Option exercise (M): 21,356 @ $1.69 · Option exercise (M): 52,584 (derivative) @ $0 · Option exercise (M): 21,356 (derivative) @ $0EDGAR
2023-11-224RENSCHLER MARKUS MD — President and CEO, DirectorOption exercise (M): 56,737 @ $1.69 · Option exercise (M): 27,900 @ $1.20 · Option exercise (M): 56,737 (derivative) @ $0 · Option exercise (M): 27,900 (derivative) @ $0EDGAR
2023-07-204Novo Holdings A/S — 10% ownerSale (S): 1,900 @ $2.76 · Sale (S): 100,000 @ $2.75EDGAR
2023-07-184Novo Holdings A/S — 10% ownerSale (S): 11,000 @ $2.74 · Sale (S): 21,100 @ $2.75 · Sale (S): 6,500 @ $2.76EDGAR
2023-07-034Novo Holdings A/S — 10% ownerSale (S): 200,937 @ $2.63EDGAR
2023-06-284Novo Holdings A/S — 10% ownerSale (S): 8,437 @ $1.79 · Sale (S): 31,978 @ $1.77EDGAR
2023-06-234Novo Holdings A/S — 10% ownerSale (S): 4,834 @ $1.99 · Sale (S): 5,041 @ $1.94 · Sale (S): 3,423 @ $1.88EDGAR
2023-06-204Novo Holdings A/S — 10% ownerSale (S): 10,002 @ $2.03 · Sale (S): 5,983 @ $2.03 · Sale (S): 744 @ $2.11EDGAR
2023-06-144Novo Holdings A/S — 10% ownerSale (S): 900 @ $2.06 · Sale (S): 2,626 @ $2.10 · Sale (S): 2,872 @ $2.11EDGAR
2023-02-074Sands Stephen H. — DirectorGrant/award (A): 12,129 (derivative) @ $0EDGAR
2023-02-074Romberger Timothy — DirectorGrant/award (A): 14,150 (derivative) @ $0EDGAR
2023-02-074Humphrey Jeffrey — DirectorGrant/award (A): 14,150 (derivative) @ $0EDGAR
2023-02-074Bracken Racquel — DirectorGrant/award (A): 14,150 (derivative) @ $0EDGAR
2023-02-074Gaiero David G — Chief Financial OfficerGrant/award (A): 5,000 @ $1.49 · Grant/award (A): 113,900 (derivative) @ $0EDGAR
2023-02-074Gaiero David G — Chief Financial OfficerOption exercise (M): 4,100 @ $1.68 · Option exercise (M): 4,100 (derivative) @ $0EDGAR
2023-02-074Veness Adam M — General CounselGrant/award (A): 96,100 (derivative) @ $0EDGAR
2023-02-074Molineaux Susan — DirectorGrant/award (A): 14,150 (derivative) @ $0EDGAR
2023-02-074Zakrzewski Joseph S — DirectorGrant/award (A): 14,150 (derivative) @ $0EDGAR
2023-02-074George Jean — DirectorGrant/award (A): 14,150 (derivative) @ $0EDGAR
2023-02-074RENSCHLER MARKUS MD — President and CEO, DirectorGrant/award (A): 5,000 @ $1.49 · Grant/award (A): 302,600 (derivative) @ $0EDGAR
2023-02-074THERO JOHN F — DirectorGrant/award (A): 12,828 (derivative) @ $0EDGAR
2022-12-234RENSCHLER MARKUS MD — President and CEO, DirectorOption exercise (M): 106,345 @ $1.03 · Option exercise (M): 30,437 @ $1.20 · Option exercise (M): 106,345 (derivative) @ $0 · Option exercise (M): 30,437 (derivative) @ $0EDGAR
2022-12-084Zakrzewski Joseph S — DirectorPurchase (P): 21,202 @ $1.30EDGAR
2022-12-084/AZakrzewski Joseph S — DirectorHoldings only — no transactions reportedEDGAR
2022-07-224Novo Holdings A/S — 10% ownerSale (S): 900,000 @ $3EDGAR
2022-05-164Zakrzewski Joseph S — DirectorPurchase (P): 743 @ $1.61EDGAR
2022-05-124Zakrzewski Joseph S — DirectorPurchase (P): 49,406 @ $1.89 · Purchase (P): 1,000 @ $1.70EDGAR
2022-05-124THERO JOHN F — DirectorPurchase (P): 10,000 @ $2EDGAR
2022-05-044Veness Adam M — General CounselGrant/award (A): 177,000 (derivative) @ $0EDGAR
2022-02-244Bracken Racquel — DirectorGrant/award (A): 14,150 (derivative) @ $0EDGAR
2022-02-244Romberger Timothy — DirectorGrant/award (A): 14,150 (derivative) @ $0EDGAR
2022-02-244Naesens Janwillem — DirectorGrant/award (A): 14,150 (derivative) @ $0EDGAR
2022-02-244Secrist John Paul — Chief Scientific OfficerGrant/award (A): 42,000 (derivative) @ $0EDGAR
2022-02-244Gaiero David G — Vice President, FinanceGrant/award (A): 23,000 (derivative) @ $0EDGAR
2022-02-244Sands Stephen H. — DirectorGrant/award (A): 28,300 (derivative) @ $0EDGAR
2022-02-244Gengos Andrew — Chief Business OfficerGrant/award (A): 35,000 (derivative) @ $0EDGAR
2022-02-244Molineaux Susan — DirectorGrant/award (A): 14,150 (derivative) @ $0EDGAR
2022-02-244Zakrzewski Joseph S — DirectorGrant/award (A): 14,150 (derivative) @ $0EDGAR
2022-02-244George Jean — DirectorGrant/award (A): 14,150 (derivative) @ $0EDGAR
2022-02-244RENSCHLER MARKUS MD — President and CEO, DirectorGrant/award (A): 106,200 (derivative) @ $0EDGAR

Recent 8-K events — Cyteir Therapeutics, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2024-03-208-K1.02 — Termination of a Material Definitive Agreement
3.03 — Material Modification to Rights of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2024-03-078-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-12-278-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2023-12-078-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2023-12-058-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2023-11-178-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2023-10-128-K8.01 — Other EventsEDGAR
2023-10-058-K1.01 — Entry into a Material Definitive AgreementEDGAR
2023-06-308-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-06-148-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=CYT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs